Found 76 clinical trials
Stop Hep B @ Birth
hepatitis B virus: antenatal tenofovir, and timely newborn administration of hepatitis B birth dose vaccine and hepatitis B immune globulin; Component II aims to achieve high coverage of screening
- 0 views
- 15 Aug, 2021
- 1 location
PrEP Affect Regulation Treatment Innovation (PARTI)
directly observed PrEP doses (PARTI+CM) compared to an attention-control condition delivered during CM. The primary outcome is HIV acquisition risk measured using a combination of tenofovir-diphosphate
- 0 views
- 27 May, 2022
- 2 locations
Chronic Hepatitis b Patients Switch to tAf After Discontinuation of Nucleoside Analogue
We will conduct a phase 4, multicenter, open-label trial at 7 academic centers in Taiwan. Chronic hepatitis B patients receiving oral antiviral therapy (entecavir [ETV], tenofovir
- 0 views
- 12 Aug, 2021
- 7 locations
Same-Day PrEP Initiation and Sexual Health for Transgender Women
emtricitabine/tenofovir alafenamide (F/TAF), a new PrEP regimen, has not to our knowledge previously been evaluated as PrEP in African trans women. F/TAF is potentially more efficacious and safer than
- 0 views
- 16 Dec, 2021
- 1 location
Three Types of Nucleotide/Nucleoside Analogues Therapy in Patients With Chronic Hepatitis b
This study is to investigate the clinical efficacy and safety of three types of nucleotide/nucleoside analogues in treatment of chronic hepatitis b
- 0 views
- 21 Feb, 2022
- 1 location
Three Types of Nucleotide/Nucleoside Analogues Therapy in Patients With Hepatitis b Virus Related Compensated Cirrhosis
This study is to investigate the clinical efficacy and safety of three types of nucleotide/nucleoside analogues in treatment of hepatitis b virus related compensated cirrhosis.
- 0 views
- 21 Feb, 2022
- 1 location
Three Types of Nucleotide/Nucleoside Analogues Treatment in HBV Related ACLF (HBV)
This study is to investigate the clinical efficacy of three types of nucleotide/nucleoside analogues in treatment of HBV-related acute-on-chronic liver failure.
- 3 views
- 03 Feb, 2022
- 1 location
Dolutegravir-Lamivudine for naïve HIV-Infected Patients With ≤200 CD4/mm3 (DOLCE)
Protocol Title: DOLCE: Dolutegravir-Lamivudine for naïve HIV-Infected Patients with ≤200 CD4/mm3 Protocol Number: FH-57 Study Objectives: To assess the antiviral activity at week 48 of DTG+3TC among naïve HIV patients with a CD4 count ≤200 cells /mm3.
- 1 views
- 09 Apr, 2023
- 4 locations
Pre-exposure Prophylaxis (PrEP) at Home (PrEP@Home)
This study is a randomized clinical trial of PrEP@Home, a home care system for Human Immunodeficiency Virus (HIV) Pre-Exposure Prophylaxis (PrEP). Individuals entering into PrEP care at an initial in-person study visit will be randomized to the PrEP@Home system for home-based PrEP care follow-up visits or to the control standard …
- 31 views
- 04 Oct, 2022
- 4 locations
Adherence and Clinical Correlates in Persons With HIV on TAF (ACT)
gold-standard measure to monitor ARV exposure and adherence that has been implemented in clinical practice. Tenofovir diphosphate (TFV-DP), the phosphorylated anabolite of tenofovir (TFV), has distinct
- 0 views
- 04 Oct, 2022
- 1 location